The discovery of PROTACs (Protein Targeting Chimeras) requires expertises and contributions from a broad variety of disciplines starting from the identification of initial binders for the target to be degraded as well as for an appropriate E3 Ligase, biophysical validation, optimization of the small-molecule binding partners and linker types by experienced medicinal chemists, characterization of PROTAC molecules in ubiquitinylation and degradation assays, permeability studies followed by investigations of metabolic stability, characterization of in vivo PK, exposure studies at the target localization of interest as well as efficacy testing. NUVISAN is able to offer the tools and expertises required for the discovery of PROTACs by making available its PROTACs platform to clients.